MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15052088

Медицинская библиотека · Journal of clinical medicine · 2026

Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey.

Bakırtaş Mehmet, Berber İlhami, Hindilerden İpek Yönal, Dal Mehmet Sinan, İzmir Güner Şebnem, Uysal Ayşe, Ekinci Ömer, Aslan Candır Burcu, Eser Bülent, Akpınar Seval, Biçim Soykan, Yiğenoğlu Tuğçe Nur, Ulaş Turgay, Turgut Burhan, Erkurt Mehmet Ali, Altuntaş Fevzi

СтатьяПеревод в очереди

Аннотация

Introduction &

Objective

Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), with limited treatment options for steroid-resistant cases. Ruxolitinib, a JAK1/2 inhibitor, has shown promise in treating steroid-resistant acute (aGVHD), chronic (cGVHD), and overlap GVHD (oGVHD), but real-world data remain limited. This study evaluated the real-world efficacy and safety of ruxolitinib in allo-HSCT patients with steroid-resistant GVHD. Materials &

Methods

This retrospective, multicenter study included adult patients treated with ruxolitinib for Grade II or higher aGVHD or moderate-to-severe cGVHD at nine centers in Turkey (2017-2024). Clinical characteristics, treatment responses, and adverse events were recorded. Primary outcomes were overall response rate (ORR) and overall survival (OS).

Results

Among 80 patients (mean age: 39.3 ± 13.3 years; 60 males), 39 had aGVHD, 68 cGVHD, and 15 oGVHD. The ORR was 72 of 80 patients (90.0%) (complete response: 37 of 80 [46.3%], partial response: 35 of 80 [43.8%]). The 1-year and 2-year OS rates were 91.3% and 82.5%. Severe cGVHD (p < 0.001) and lack of response to ruxolitinib (p = 0.018) were associated with reduced OS. Adverse events included infections in 40 of 80 patients (50.0%), cytopenias in 23 of 80 (28.7%), and cytomegalovirus reactivation in 20 of 80 (25.0%).

Conclusion

In this retrospective multicenter cohort, ruxolitinib was associated with high response rates in steroid-refractory GVHD, while disease severity remained a key determinant of survival, and findings should be interpreted as exploratory.

Для цитирования: Bakırtaş Mehmet, Berber İlhami, Hindilerden İpek Yönal, Dal Mehmet Sinan, İzmir Güner Şebnem, Uysal Ayşe, Ekinci Ömer, Aslan Candır Burcu, Eser Bülent, Akpınar Seval, Biçim Soykan, Yiğenoğlu Tuğçe Nur, Ulaş Turgay, Turgut Burhan, Erkurt Mehmet Ali, Altuntaş Fevzi. Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15052088.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.